Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Merck Sharp & Dohme Corp.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01986881
First received: November 12, 2013
Last updated: August 20, 2014
Last verified: August 2014
  Purpose

A study of the cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and established vascular disease. The main objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial includes a pre-defined glycemic sub-study in participants receiving background insulin with or without metformin and another pre-defined glycemic sub-study in participants receiving background sulfonylurea monotherapy.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: Ertugliflozin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Time to First Occurrence of Any Component of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke [ Time Frame: Up to 6.3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Time to First Occurrence of any of the Components of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina [ Time Frame: Up to 6.3 years ] [ Designated as safety issue: Yes ]
  • Number of Participants Experiencing An Adverse Event (AE) [ Time Frame: Up to 6.3 years ] [ Designated as safety issue: Yes ]
  • Number of Participants Discontinuing Study Treatment Due to an AE [ Time Frame: Up to 6.3 years ] [ Designated as safety issue: Yes ]
  • Change from Baseline In Hemoglobin A1c (HbA1c) at Week 18 [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Change from Baseline In HbA1c at the End of Study (up to 6.3 years) [ Time Frame: Baseline and at the End of Study (up to 6.3 years) ] [ Designated as safety issue: No ]
  • Change from Baseline in Fasting Plasma Glucose (FPG) at Week 18 [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Change from Baseline in Body Weight at Week 18 [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Change from Baseline in Body Weight at the End of Study (up to 6.3 years) [ Time Frame: Baseline and at the End of Study (up to 6.3 years) ] [ Designated as safety issue: No ]
  • Number of Participants with a HbA1c <7% at Week 18 [ Time Frame: Week 18 ] [ Designated as safety issue: No ]
  • Number of Participants with a HbA1c <7% at the End of Study (up to 6.3 years) [ Time Frame: At the End of Study (up to 6.3 years) ] [ Designated as safety issue: No ]
  • Change from Baseline in Systolic Blood Pressure at Week 18 [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Change from Baseline in Systolic Blood Pressure at the End of Study (up to 6.3 years) [ Time Frame: Baseline and at the End of Study (up to 6.3 years) ] [ Designated as safety issue: No ]
  • Change from Baseline in Diastolic Blood Pressure at Week 18 [ Time Frame: Baseline and Week 18 ] [ Designated as safety issue: No ]
  • Change from Baseline in Diastolic Blood Pressure at the End of Study (up to 6.3 years) [ Time Frame: Baseline and at the End of Study (up to 6.3 years) ] [ Designated as safety issue: No ]

Estimated Enrollment: 3900
Study Start Date: November 2013
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ertugliflozin, 15 mg
Ertugliflozin 15 mg administered orally once daily for up to 6.3 years
Drug: Ertugliflozin
Oral, once daily, up to 6.3 years
Other Name: MK-8835
Experimental: Ertugliflozin, 5 mg
Ertugliflozin 5 mg administered orally once daily for up to 6.3 years
Drug: Ertugliflozin
Oral, once daily, up to 6.3 years
Other Name: MK-8835
Drug: Placebo
Matching placebo to ertugliflozin administered orally once daily for up to 6.3 years
Placebo Comparator: Placebo
Matching placebo to ertugliflozin administered orally once daily for up to 6.3 years
Drug: Placebo
Matching placebo to ertugliflozin administered orally once daily for up to 6.3 years

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of T2DM in accordance with American Diabetes Association (ADA) guidelines
  • Hemoglobin A1c (HbA1c) at the start of study participation of 7.0-10.5% (53-91 mmol/mol)
  • On stable allowable anti-hyperglycemic agents (AHA) or on no background AHA for at least 8 weeks prior to the study participation
  • Body Mass Index (BMI) > or = to 18.0 kg/m^2
  • Evidence or a history of atherosclerosis involving the coronary, cerebral or peripheral vascular systems
  • Male, female not or reproductive potential, or female of reproductive potential who agrees to be abstinent from heterosexual activity or agrees to use or have their partner use 2 acceptable methods of contraception
  • Additional Inclusion Criteria Specific to the Insulin +/- Metformin Add-on Glycemic Sub-Study
  • Insulin >=20 units/day with or without metformin >=1,500 mg/day stable doses for at least 8 weeks prior to study participation
  • Additional Inclusion Criteria Specific to the sulfonylurea (SU) Monotherapy Add-on Glycemic Sub-Study
  • Monotherapy with an acceptable dose of a SU. The dose of the SU monotherapy must have been stable for at least 8 weeks prior to study participation.

Exclusion Criteria:

  • Previous randomization into a trial of ertugliflozin
  • Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening Visit and randomization
  • Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study participation
  • Planned revascularization or peripheral intervention procedure or other cardiovascular surgery
  • New York Heart Association (NYHA) Class III or IV heart failure at study participation
  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • Additional Exclusion Criteria Specific to the Insulin +/- Metformin Add-on Glycemic Sub-Study
  • Use of prandial insulin alone without basal insulin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01986881

Contacts
Contact: Toll Free Number 1-888-577-8839

  Hide Study Locations
Locations
United States, Alabama
Call for Information (Investigational Site 1431) Recruiting
Birmingham, Alabama, United States, 35209
United States, Arizona
Call for Information (Investigational Site 1699) Recruiting
Chandler, Arizona, United States, 85224
Call for Information (Investigational Site 1634) Recruiting
Gilbert, Arizona, United States, 85295
Call for Information (Investigational Site 1423) Recruiting
Phoenix, Arizona, United States, 85018
Call for Information (Investigational Site 1693) Recruiting
Phoenix, Arizona, United States, 35032
Call for Information (Investigational Site 1105) Recruiting
Tucson, Arizona, United States, 85724
United States, Arkansas
Call for Information (Investigational Site 1705) Recruiting
Little Rock, Arkansas, United States, 72209
United States, California
Call for Information (Investigational Site 1879) Recruiting
Fresno, California, United States, 93721
Call for Information (Investigational Site 1043) Recruiting
Harbor City, California, United States, 90710
Call for Information (Investigational Site 1061) Recruiting
Los Angeles, California, United States, 90022
Call for Information (Investigational Site 1441) Recruiting
North Hollywood, California, United States, 91606
Call for Information (Investigational Site 1092) Recruiting
Santa Ana, California, United States, 92704
Call for Information (Investigational Site 1048) Recruiting
Torrance, California, United States, 90502
Call for Information (Investigational Site 1437) Recruiting
Tustin, California, United States, 92780
United States, Colorado
Call for Information (Investigational Site 1443) Recruiting
Colorado Springs, Colorado, United States, 80906
United States, Florida
Call for Information (Investigational Site 1700) Recruiting
Boynton Beach, Florida, United States, 33472
Call for Information (Investigational Site 1054) Recruiting
Clearwater, Florida, United States, 33756
Call for Information (Investigational Site 1810) Recruiting
Delray Beach, Florida, United States, 33484
Call for Information (Investigational Site 1041) Recruiting
Gainesville, Florida, United States, 32605
Call for Information (Investigational Site 1104) Recruiting
Hialeah, Florida, United States, 33012
Call for Information (Investigational Site 1724) Recruiting
Lauderdale Lakes, Florida, United States, 33319
Call for Information (Investigational Site 1071) Recruiting
Lynn Haven, Florida, United States, 32444
Call for Information (Investigational Site 1590) Recruiting
Miami, Florida, United States, 33135
Call for Information (Investigational Site 1766) Recruiting
Miami, Florida, United States, 33155
Call for Information (Investigational Site 1399) Recruiting
Oakland Park, Florida, United States, 33309
Call for Information (Investigational Site 1451) Recruiting
Orlando, Florida, United States, 32804
Call for Information (Investigational Site 1818) Recruiting
Orlando, Florida, United States, 32806
Call for Information (Investigational Site 1131) Recruiting
Orlando, Florida, United States, 32825
Call for Information (Investigational Site 1094) Recruiting
Ormond Beach, Florida, United States, 32174
Call for Information (Investigational Site 1084) Recruiting
Palm Harbor, Florida, United States, 34684
Call for Information (Investigational Site 1805) Recruiting
Sarasota, Florida, United States, 34239-3513
Call for Information (Investigational Site 1430) Recruiting
Tampa, Florida, United States, 33613
United States, Georgia
Call for Information (Investigational Site 1646) Recruiting
Atlanta, Georgia, United States, 30303
Call for Information (Investigational Site 1398) Recruiting
Calhoun, Georgia, United States, 30701
Call for Information (Investigational Site 1438) Recruiting
Lawrenceville, Georgia, United States, 30046
Call for Information (Investigational Site 1087) Recruiting
Savannah, Georgia, United States, 31419
United States, Indiana
Call for Information (Investigational Site 1097) Recruiting
Avon, Indiana, United States, 46123
Call for Information (Investigational Site 1688) Recruiting
Evansville, Indiana, United States, 47714
Call for Information (Investigational Site 1452) Recruiting
Franklin, Indiana, United States, 46131
United States, Iowa
Call for Information (Investigational Site 1407) Recruiting
Ames, Iowa, United States, 50010
Call for Information (Investigational Site 1881) Recruiting
Council Bluffs, Iowa, United States, 51501
United States, Louisiana
Call for Information (Investigational Site 1067) Recruiting
Alexandria, Louisiana, United States, 71301
Call for Information (Investigational Site 1767) Recruiting
Hammond, Louisiana, United States, 70403
Call for Information (Investigational Site 1068) Recruiting
Metairie, Louisiana, United States, 70006
Call for Information (Investigational Site 1089) Recruiting
Monroe, Louisiana, United States, 71203
United States, Maine
Call for Information (Investigational Site 1445) Recruiting
Lewiston, Maine, United States, 04240
United States, Massachusetts
Call for Information (Investigational Site 1375) Recruiting
Fall River, Massachusetts, United States, 02721
Call for Information (Investigational Site 1074) Recruiting
Watertown, Massachusetts, United States, 02472
United States, Michigan
Call for Information (Investigational Site 1652) Recruiting
Detroit, Michigan, United States, 48202
Call for Information (Investigational Site 1582) Recruiting
Flint, Michigan, United States, 48504
Call for Information (Investigational Site 1137) Recruiting
Flint, Michigan, United States, 48503
United States, Nebraska
Call for Information (Investigational Site 1878) Recruiting
Lincoln, Nebraska, United States, 68516
Call for Information (Investigational Site 1676) Recruiting
Omaha, Nebraska, United States, 63114
United States, Nevada
Call for Information (Investigational Site 1081) Recruiting
Las Vegas, Nevada, United States, 89148
United States, New Jersey
Call for Information (Investigational Site 1464) Recruiting
Bridgewater, New Jersey, United States, 08807-3060
Call for Information (Investigational Site 1082) Recruiting
Elizabeth, New Jersey, United States, 07202
Call for Information (Investigational Site 1063) Recruiting
Haddon Heights, New Jersey, United States, 08035
United States, New Mexico
Call for Information (Investigational Site 1696) Recruiting
Albuquerque, New Mexico, United States, 87108
United States, New York
Call for Information (Investigational Site 1058) Recruiting
Glens Falls, New York, United States, 12801
Call for Information (Investigational Site 1035) Recruiting
Rosedale, New York, United States, 11422
United States, North Carolina
Call for Information (Investigational Site 1771) Recruiting
Calabash, North Carolina, United States, 28467
Call for Information (Investigational Site 1090) Recruiting
Lenoir, North Carolina, United States, 28645
United States, North Dakota
Call for Information (Investigational Site 1076) Recruiting
Fargo, North Dakota, United States, 58103
United States, Ohio
Call for Information (Investigational Site 1080) Recruiting
Columbus, Ohio, United States, 43235
Call for Information (Investigational Site 1088) Recruiting
Kettering, Ohio, United States, 45429
Call for Information (Investigational Site 1039) Recruiting
Marion, Ohio, United States, 43302
Call for Information (Investigational Site 1053) Recruiting
Maumee, Ohio, United States, 43537
United States, Oklahoma
Call for Information (Investigational Site 1462) Recruiting
Bartlesville, Oklahoma, United States, 74006
Call for Information (Investigational Site 1721) Recruiting
Oklahoma City, Oklahoma, United States, 73135
United States, Pennsylvania
Call for Information (Investigational Site 1045) Recruiting
Altoona, Pennsylvania, United States, 16602
Call for Information (Investigational Site 1587) Recruiting
Perkasie, Pennsylvania, United States, 18944
United States, South Carolina
Call for Information (Investigational Site 1069) Recruiting
Murrells Inlet, South Carolina, United States, 29576
United States, Texas
Call for Information (Investigational Site 1691) Recruiting
Arlington, Texas, United States, 76014
Call for Information (Investigational Site 1424) Recruiting
Dallas, Texas, United States, 75390-8857
Call for Information (Investigational Site 1057) Recruiting
Dallas, Texas, United States, 75235
Call for Information (Investigational Site 1408) Recruiting
Houston, Texas, United States, 77024
Call for Information (Investigational Site 1446) Recruiting
Houston, Texas, United States, 77074
Call for Information (Investigational Site 1803) Recruiting
Houston, Texas, United States, 77036
Call for Information (Investigational Site 1128) Recruiting
Houston, Texas, United States, 77450
Call for Information (Investigational Site 1102) Recruiting
Katy, Texas, United States, 77450
Call for Information (Investigational Site 1701) Recruiting
San Antonio, Texas, United States, 78217
Call for Information (Investigational Site 1694) Recruiting
San Antonio, Texas, United States, 78258
Call for Information (Investigational Site 1083) Recruiting
San Antonio, Texas, United States, 78238
Call for Information (Investigational Site 1773) Recruiting
San Antonio, Texas, United States, 78228
Call for Information (Investigational Site 1036) Recruiting
Schertz, Texas, United States, 78154
Call for Information (Investigational Site 1498) Recruiting
Spring, Texas, United States, 77379
Call for Information (Investigational Site 1589) Recruiting
Tomball, Texas, United States, 77375
United States, Utah
Call for Information (Investigational Site 1499) Recruiting
Murray, Utah, United States, 84123
United States, Virginia
Call for Information (Investigational Site 1768) Recruiting
Manassas, Virginia, United States, 20110
Call for Information (Investigational Site 1448) Recruiting
Richmond, Virginia, United States, 23235
Call for Information (Investigational Site 1415) Recruiting
Salem, Virginia, United States, 24153
Call for Information (Investigational Site 1574) Recruiting
Suffolk, Virginia, United States, 23435-3763
Call for Information (Investigational Site 1136) Recruiting
Winchester, Virginia, United States, 22601
United States, Washington
Call for Information (Investigational Site 1050) Recruiting
Spokane, Washington, United States, 99207
Call for Information (Investigational Site 1046) Recruiting
Tacoma, Washington, United States, 98405
Call for Information (Investigational Site 1044) Recruiting
Walla Walla, Washington, United States, 99362
United States, Wisconsin
Call for Information (Investigational Site 1073) Recruiting
Green Bay, Wisconsin, United States, 54303
Call for Information (Investigational Site 1392) Recruiting
Kenosha, Wisconsin, United States, 53142
Australia
Merck Sharp & Dohme Recruiting
North Ryde, Australia
Contact: Gary Jankelowitz    61 2 8988 8246      
Bulgaria
Merck Sharp & Dohme Bulgaria EOOD Recruiting
Sofia, Bulgaria
Contact: Eran Gefen    38 (044) 393 74 80      
Canada, Quebec
Merck Canada Recruiting
Kirkland, Quebec, Canada, H9H 3L1
Contact: Medical Information Centre / Centre de l'information medicale de Merck Canada    514-428-8600 / 1-800-567-2594      
Croatia
Merck Sharp & Dohme d.o.o Recruiting
Zagreb, Croatia
Contact: Andina Hrabar    385 14878400      
Georgia
Merck Sharp & Dohme IDEA, Inc. Recruiting
Tbilisi, Georgia
Contact: Eran Gefen    38 (044) 393 74 80      
Hong Kong
Merck Sharp & Dohme (Asia) Ltd. Recruiting
Hong Kong, Hong Kong
Contact: Lai Hung Jen    886 2 2730 0030      
Israel
Merck Sharp & Dohme Co. Ltd. Recruiting
Hod Hasharon, Israel
Contact: Ofer Sharon    972 9 9539310      
Korea, Republic of
MSD Korea LTD Recruiting
Seoul, Korea, Republic of
Contact: Cem Ozesen    90 212 3361260      
Netherlands
Merck Sharp & Dohme BV Recruiting
Haarlem, Netherlands
Contact: Caroline Doornebos    31 23 515 3362      
New Zealand
Merck Sharp & Dohme (New Zealand) Ltd., Recruiting
Wellington, New Zealand
Contact: Gary Jankelowitz    61 2 8988 8246      
Poland
MSD Polska Sp. Z o.o. Recruiting
Warsaw, Poland
Contact: Adam Czernik    48 22 4784324      
Russian Federation
Merck Sharp & Dohme IDEA, Inc. Recruiting
Moscow, Russian Federation
Contact: Maria Koroleva    7 0959410000      
South Africa
MSD (Pty) LTD South Africa Recruiting
Midrand, South Africa
Contact: Khanyi Mzolo    27 11 655 3140      
Sweden
MSD Recruiting
Sollentuna, Sweden
Contact: Tryggve Ljung    46 (0)70 545 28 66      
Taiwan
Merck Sharp & Dohme (I.A.) Corp. Recruiting
Taipei, Taiwan
Contact: Diana Zhang    886-2-66316030      
Thailand
MSD (Thailand) Ltd. Recruiting
Bangkok, Thailand
Contact: Thanu Komolsai    66 2262 5746      
Turkey
Merck Sharp & Dohme Ilaclari Ltd. Sti Recruiting
Istanbul, Turkey
Contact: Alev Eren    90 212 336 12 63      
United Kingdom
Merck Sharp & Dohme Ltd. Recruiting
Hoddesdon, United Kingdom
Contact: Paul Robinson    44 1992452396      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Pfizer
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01986881     History of Changes
Other Study ID Numbers: 8835-004, 2013-002518-11
Study First Received: November 12, 2013
Last Updated: August 20, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Vascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 26, 2014